Literature DB >> 15930806

Cardiovascular risk factors in hemodialysis patients: results from baseline data of kaleidoscopic approaches to patients with end-stage renal disease study.

Masaki Ohsawa1, Karen Kato, Kazuyoshi Itai, Toshiyuki Onoda, Ryuichiro Konda, Tomoaki Fujioka, Motoyuki Nakamura, Akira Okayama.   

Abstract

BACKGROUND: The prevalence of cardiovascular risk factors and the prevalence of comorbidities in adult hemodialysis patients in Japan are not fully understood.
METHODS: In "Kaleidoscopic Approaches to Patients with End-stage Renal Disease Study" (The KAREN Study, 2003), trained research stuff examined 1,214 adult hemodialysis patients (mean age, 61.2 years; 779 males and 435 females) of 1,506 patients in northern areas of Iwate Prefecture. Cardiovascular risk factors and the prevalence of comorbidities in hemodialysis patients were compared with those in the general population using direct age-adjustment methodology and standardized morbidity ratios (SMRs).
RESULTS: In hemodialysis patients, common causes of end-stage renal disease were chronic glomerulonephritis (29.8%), diabetic nephropathy (24.5%), and other diseases. Prevalence and SMR of myocardial infarction were 5% and 9.6, respectively, and those of stroke were 13% and 5.7. The prevalences of hypertension and diabetes mellitus were 87% and 29%, respectively. Mean systolic blood pressure and mean diastolic blood pressure were 155 mmHg and 85 mmHg, respectively. Mean levels of total serum cholesterol, high-density lipoprotein cholesterol, and albumin in patients with end-stage renal disease were lower than those of the general population (160.6 vs. 203.3 mg/dL, 48.5 vs. 59.7 mg/dL, and 3.7 vs. 4.4 g/dL, respectively). Mean levels of C-reactive protein were higher than those of the general population (3.80 vs. 1.16 mg/L).
CONCLUSION: Hemodialysis patients have a high prevalence of cardiovascular risk factors and comorbidities. Levels of nutrition-related markers were lower, and C-reactive protein levels were higher, in hemodialysis patients than in the general population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930806     DOI: 10.2188/jea.15.96

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


  5 in total

1.  Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver disease-related mortality in hemodialysis patients.

Authors:  Masaki Ohsawa; Karen Kato; Kozo Tanno; Kazuyoshi Itai; Yosuke Fujishima; Akira Okayama; Tanvir Chowdhury Turin; Toshiyuki Onoda; Kazuyuki Suzuki; Motoyuki Nakamura; Kazuko Kawamura; Takashi Akiba; Kiyomi Sakata; Tomoaki Fujioka
Journal:  J Epidemiol       Date:  2011-10-15       Impact factor: 3.211

2.  Prevalence of cardiovascular risk factors in hemodialysis patients - The CORDIAL study.

Authors:  Jayme Eduardo Burmeister; Camila Borges Mosmann; Veridiana Borges Costa; Ramiro Tubino Saraiva; Renata Rech Grandi; Juliano Peixoto Bastos; Luiz Felipe Gonçalves; Guido Aranha Rosito
Journal:  Arq Bras Cardiol       Date:  2014-04-17       Impact factor: 2.000

3.  Prognostic performance of combined use of high-sensitivity troponin T and creatine kinase MB isoenzyme in high cardiovascular risk patients with end-stage renal disease.

Authors:  Khaled Abdul-Aziz Ahmed; Wahda Mohammed Al-Attab
Journal:  Kidney Res Clin Pract       Date:  2017-12-31

4.  Standardized prevalence ratios for chronic hepatitis C virus infection among adult Japanese hemodialysis patients.

Authors:  Masaki Ohsawa; Karen Kato; Kazuyoshi Itai; Kozo Tanno; Yosuke Fujishima; Ryuichiro Konda; Akira Okayama; Koichi Abe; Kazuyuki Suzuki; Motoyuki Nakamura; Toshiyuki Onoda; Kazuko Kawamura; Kiyomi Sakata; Takashi Akiba; Tomoaki Fujioka
Journal:  J Epidemiol       Date:  2009-10-31       Impact factor: 3.211

5.  Standardized Prevalence Ratios for Atrial Fibrillation in Adult Dialysis Patients in Japan.

Authors:  Masaki Ohsawa; Kozo Tanno; Tomonori Okamura; Yuki Yonekura; Karen Kato; Yosuke Fujishima; Wataru Obara; Takaya Abe; Kazuyoshi Itai; Kuniaki Ogasawara; Shinichi Omama; Tanvir Chowdhury Turin; Naomi Miyamatsu; Yasuhiro Ishibashi; Yoshihiro Morino; Tomonori Itoh; Toshiyuki Onoda; Toru Kuribayashi; Shinji Makita; Yuki Yoshida; Motoyuki Nakamura; Fumitaka Tanaka; Mutsuko Ohta; Kiyomi Sakata; Akira Okayama
Journal:  J Epidemiol       Date:  2016-01-23       Impact factor: 3.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.